Close

Pfizer Phase 3 fibromyalgia study of pregabalin meets primary endpoint

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients.

The primary endpoint of the placebo-controlled, multi-center study was achieved in 54% patients administered with pregabalin, compared to 70.7% patients in the placebo group.

A statistically significant difference between the treatments was observed in the study in which pregabalin was well tolerated.

Study reported median time from randomization to LTR of 58 days in pregabalin group and 22 days in the placebo group.

Pfizer global primary care business unit, medicines development group, head and senior vice president Steven Romano said the results from controlled release studies will help in better understanding of the potential of a once-a-day pregabalin treatment regimen.

“Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes,” Romano added.

The randomized, double-blind study is the second of the three Phase III studies designed to assess the potential use of pregabalin as once daily therapy.

First one conducted in adults with partial onset seizures with epilepsy failed to meet the goal while the third one in post-herpetic neuralgia is going on.

Latest stories

Related stories

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back